Catalog No.
DHC12505
Description
Solanezumab is a humanized monoclonal IgG1 antibody directed against the mid-domain of the Aβ peptide. It recognizes soluble monomeric, not fibrillar, Aβ. Solanezumab (formerly known as LY2062430) is a monoclonal antibody being developed by Lilly as a potential therapy for people with mild cognitive impairment caused by Alzheimer’s disease.
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
AICD-57, A4, Beta-CTF, Protease nexin-II, Gamma-CTF(50), ABPP, S-APP-beta, APP, Abeta40, Abeta42, AID(59), Amyloid intracellular domain 59, AID(57), S-APP-alpha, Gamma-CTF(59), Beta-secretase C-terminal fragment, Amyloid-beta precursor protein, Amyloid precursor protein, Beta-APP42, PreA4, Alzheimer disease amyloid protein, APPI, PN-II, AICD-59, Alpha-secretase C-terminal fragment, Amyloid-beta A4 protein, Amyloid intracellular domain 57, CVAP, Amyloid intracellular domain 50, Beta-APP40, AD1, Cerebral vascular amyloid peptide, AID(50), Alpha-CTF, Gamma-CTF(57), AICD-50
Concentration
1.8 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P05067
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
LY2062430, CAS: 955085-14-0
Clone ID
Solanezumab
Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease, PMID: 29365294
Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients, PMID: 26238576
Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease, PMID: 24450890
Solanezumab for Alzheimer's disease, PMID: 21504387
The amyloid hypothesis of Alzheimer's disease at 25 years, PMID: 27025652
Solanezumab for the treatment of mild-to-moderate Alzheimer's disease, PMID: 22288451
Central pharmacodynamic activity of solanezumab in mild Alzheimer's disease dementia, PMID: 30511011
Bapineuzumab and solanezumab for Alzheimer's disease: is the 'amyloid cascade hypothesis' still alive?, PMID: 23574434
Grasping at straws: the failure of solanezumab to modify mild Alzheimer's disease, PMID: 30376649
Solanezumab: too late in mild Alzheimer's disease?, PMID: 28102152
Solanezumab and the amyloid hypothesis for Alzheimer's disease, PMID: 28034844
Anti-amyloid-β protein agents for the treatment of Alzheimer's disease: an update on emerging drugs, PMID: 32772738
Pathways Connecting Late-Life Depression and Dementia, PMID: 32231570
Kinetic fingerprints differentiate the mechanisms of action of anti-Aβ antibodies, PMID: 32989305
Passive antiamyloid immunotherapy for Alzheimer's disease, PMID: 32040044
The potential of solanezumab and gantenerumab to prevent Alzheimer's disease in people with inherited mutations that cause its early onset, PMID: 29037101
Molecular Docking and Dynamic Simulation of AZD3293 and Solanezumab Effects Against BACE1 to Treat Alzheimer's Disease, PMID: 29910719
Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β, PMID: 29686315
Amyloid-related imaging abnormalities from trials of solanezumab for Alzheimer's disease, PMID: 27239538
Lessons Learnt from the Second Generation of Anti-Amyloid Monoclonal Antibodies Clinical Trials, PMID: 33321511
Quantile regression to characterize solanezumab effects in Alzheimer's disease trials, PMID: 29067306
The Integrated Alzheimer's Disease Rating Scale (iADRS) Findings from the EXPEDITION3 Trial, PMID: 29616706
Delayed-start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 years, PMID: 29854931
Efficacy and safety of anti-amyloid- β immunotherapy for Alzheimer's disease: a systematic review and network meta-analysis, PMID: 29296624
Sixty seconds on . . . solanezumab, PMID: 27899350
The preclinical Alzheimer cognitive composite: measuring amyloid-related decline, PMID: 24886908
Alzheimer disease: Solanezumab-prospects for meaningful interventions in AD?, PMID: 26526537
Chemical and neuropathological analyses of an Alzheimer's disease patient treated with solanezumab, PMID: 27725918
The Failure of Solanezumab - How the FDA Saved Taxpayers Billions, PMID: 28467878
A Combined Measure of Cognition and Function for Clinical Trials: The Integrated Alzheimer's Disease Rating Scale (iADRS), PMID: 27019841
Comparison of pharmacokinetics, pharmacodynamics, safety, and tolerability of the amyloid β monoclonal antibody solanezumab in Japanese and white patients with mild to moderate alzheimer disease, PMID: 22134132
Abeta targets of the biosimilar antibodies of Bapineuzumab, Crenezumab, Solanezumab in comparison to an antibody against N‑truncated Abeta in sporadic Alzheimer disease cases and mouse models, PMID: 26467270
Delayed-Start Analyses in the Phase 3 Solanezumab EXPEDITION3 Study in Mild Alzheimer's Disease, PMID: 29405226
Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis, PMID: 31831056
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease, PMID: 34155411
Delayed-start analysis for demonstrating disease modification of solanezumab, PMID: 29854938
Anti-Aβ agents for mild to moderate Alzheimer's disease: systematic review and meta-analysis, PMID: 33046560
Validation of assays for measurement of amyloid-β peptides in cerebrospinal fluid and plasma specimens from patients with Alzheimer's disease treated with solanezumab, PMID: 23302661
Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease, PMID: 24716688
Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease, PMID: 24716689
Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease, PMID: 24724181
Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease, PMID: 24716687
Use of white matter reference regions for detection of change in florbetapir positron emission tomography from completed phase 3 solanezumab trials, PMID: 28365320
Safety and biomarker effects of solanezumab in patients with Alzheimer's disease, PMID: 22672770
Recent trial shows that solanezumab has disease modifying effects, PMID: 26318507
[Immunotherapy for Alzheimer's disease], PMID: 26815584
Early Dementia Screening, PMID: 26838803
Need for a trial of solanezumab in mild Alzheimer's disease, PMID: 26330409
Mutual population-shift driven antibody-peptide binding elucidated by molecular dynamics simulations, PMID: 31996730
Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return?, PMID: 24981190
For research use only. Not for human or drug use.
